Patient presenting features according to BMI
. | Underweight . | Normal . | At risk of overweight . | Overweight . | P . |
|---|---|---|---|---|---|
| No. patients | 102 | 400 | 64 | 55 | |
| Median age, y (range) | 4.87 (1.19-17.65) | 5.85 (1.01-18.80) | 6.40 (1.20-18.2) | 8.76 (1.27-17.5) | .168 |
| 1-9 y old, no. (%) | 79 (77.5) | 281 (70.3) | 42 (65.6) | 34 (61.8) | |
| 10 y old or older, no. (%) | 23 (22.5) | 119 (29.8) | 22 (38.2) | 21 (38.2) | |
| Sex, no. (%) | .358 | ||||
| Male | 48 (47.1) | 226 (56.5) | 36 (56.3) | 32 (58.2) | |
| Female | 54 (52.9) | 174 (43.5) | 28 (43.8) | 23 (41.8) | |
| Race, no. (%) | .118 | ||||
| White | 75 (73.5) | 330 (82.5) | 46 (71.9) | 44 (80.0) | |
| Black | 17 (16.7) | 51 (12.8) | 13 (20.3) | 10 (18.2) | |
| Other | 10 (9.8) | 19 (4.8) | 5 (7.8) | 1 (1.8) | |
| WBC count, no. (%) | .870 | ||||
| Less than 50 × 109/L | 80 (78.4) | 298 (74.5) | 48 (75.0) | 42 (6.4) | |
| At least 50 × 109/L | 22 (21.6) | 102 (25.5) | 16 (25.0) | 13 (23.6) | |
| Immunophenotype, no. (%) | .066 | ||||
| B lineage | 93 (91.2) | 324 (81.0) | 51 (79.7) | 48 (87.3) | |
| T cell | 9 (8.8) | 76 (19.0) | 13 (20.3) | 7 (12.7) | |
| DNA index, no. (%) | .068 | ||||
| At least 1.16 | 30 (29.4) | 94 (23.5) | 17 (26.6) | 6 (10.9) | |
| Less than 1.16 | 72 (70.6) | 306 (76.5) | 47 (73.4) | 49 (89.1) | |
| CNS status, no. (%) | .208 | ||||
| CNS-2 or -3* | 31 (30.4) | 137 (34.3) | 26 (40.6) | 25 (45.5) | |
| CNS-1 | 71 (69.6) | 263 (65.8) | 38 (59.4) | 30 (54.5) | |
| Philadelphia chromosome, no. (%) | .865† | ||||
| Absent | 98 (96.1) | 382 (95.5) | 62 (96.9) | 52 (94.5) | |
| Present | 4 (3.9) | 13 (3.3) | 1 (1.6) | 2 (3.6) | |
| Unknown | 0 (0) | 5 (1.3) | 1 (1.6) | 1 (1.8) | |
| TEL-AML1, no. (%) | .496† | ||||
| Absent | 59 (57.8) | 215 (53.8) | 30 (46.9) | 32 (58.2) | |
| Present | 23 (22.5) | 76 (19.0) | 12 (18.8) | 6 (10.9) | |
| Unknown | 20 (19.6) | 109 (27.3) | 22 (34.4) | 17 (30.9) | |
| MLL-AF4, no. (%) | .071† | ||||
| Absent | 100 (98.0) | 389 (97.3) | 63 (98.4) | 51 (92.7) | |
| Present | 0 (0) | 3 (0.8) | 0 (0) | 2 (3.6) | |
| Unknown | 2 (2.0) | 8 (2.0) | 1 (1.6) | 2 (3.6) | |
| Protocol, no. (%) | .537 | ||||
| Total XII | 32 (31.4) | 120 (30.0) | 18 (28.1) | 10 (18.2) | |
| Total XIIIA | 23 (22.5) | 104 (26.0) | 19 (29.7) | 14 (25.5) | |
| Total XIIIB | 41 (40.2) | 147 (36.8) | 20 (31.3) | 24 (43.6) | |
| Total XIV | 6 (5.9) | 29 (7.3) | 7 (10.9) | 7 (12.7) |
. | Underweight . | Normal . | At risk of overweight . | Overweight . | P . |
|---|---|---|---|---|---|
| No. patients | 102 | 400 | 64 | 55 | |
| Median age, y (range) | 4.87 (1.19-17.65) | 5.85 (1.01-18.80) | 6.40 (1.20-18.2) | 8.76 (1.27-17.5) | .168 |
| 1-9 y old, no. (%) | 79 (77.5) | 281 (70.3) | 42 (65.6) | 34 (61.8) | |
| 10 y old or older, no. (%) | 23 (22.5) | 119 (29.8) | 22 (38.2) | 21 (38.2) | |
| Sex, no. (%) | .358 | ||||
| Male | 48 (47.1) | 226 (56.5) | 36 (56.3) | 32 (58.2) | |
| Female | 54 (52.9) | 174 (43.5) | 28 (43.8) | 23 (41.8) | |
| Race, no. (%) | .118 | ||||
| White | 75 (73.5) | 330 (82.5) | 46 (71.9) | 44 (80.0) | |
| Black | 17 (16.7) | 51 (12.8) | 13 (20.3) | 10 (18.2) | |
| Other | 10 (9.8) | 19 (4.8) | 5 (7.8) | 1 (1.8) | |
| WBC count, no. (%) | .870 | ||||
| Less than 50 × 109/L | 80 (78.4) | 298 (74.5) | 48 (75.0) | 42 (6.4) | |
| At least 50 × 109/L | 22 (21.6) | 102 (25.5) | 16 (25.0) | 13 (23.6) | |
| Immunophenotype, no. (%) | .066 | ||||
| B lineage | 93 (91.2) | 324 (81.0) | 51 (79.7) | 48 (87.3) | |
| T cell | 9 (8.8) | 76 (19.0) | 13 (20.3) | 7 (12.7) | |
| DNA index, no. (%) | .068 | ||||
| At least 1.16 | 30 (29.4) | 94 (23.5) | 17 (26.6) | 6 (10.9) | |
| Less than 1.16 | 72 (70.6) | 306 (76.5) | 47 (73.4) | 49 (89.1) | |
| CNS status, no. (%) | .208 | ||||
| CNS-2 or -3* | 31 (30.4) | 137 (34.3) | 26 (40.6) | 25 (45.5) | |
| CNS-1 | 71 (69.6) | 263 (65.8) | 38 (59.4) | 30 (54.5) | |
| Philadelphia chromosome, no. (%) | .865† | ||||
| Absent | 98 (96.1) | 382 (95.5) | 62 (96.9) | 52 (94.5) | |
| Present | 4 (3.9) | 13 (3.3) | 1 (1.6) | 2 (3.6) | |
| Unknown | 0 (0) | 5 (1.3) | 1 (1.6) | 1 (1.8) | |
| TEL-AML1, no. (%) | .496† | ||||
| Absent | 59 (57.8) | 215 (53.8) | 30 (46.9) | 32 (58.2) | |
| Present | 23 (22.5) | 76 (19.0) | 12 (18.8) | 6 (10.9) | |
| Unknown | 20 (19.6) | 109 (27.3) | 22 (34.4) | 17 (30.9) | |
| MLL-AF4, no. (%) | .071† | ||||
| Absent | 100 (98.0) | 389 (97.3) | 63 (98.4) | 51 (92.7) | |
| Present | 0 (0) | 3 (0.8) | 0 (0) | 2 (3.6) | |
| Unknown | 2 (2.0) | 8 (2.0) | 1 (1.6) | 2 (3.6) | |
| Protocol, no. (%) | .537 | ||||
| Total XII | 32 (31.4) | 120 (30.0) | 18 (28.1) | 10 (18.2) | |
| Total XIIIA | 23 (22.5) | 104 (26.0) | 19 (29.7) | 14 (25.5) | |
| Total XIIIB | 41 (40.2) | 147 (36.8) | 20 (31.3) | 24 (43.6) | |
| Total XIV | 6 (5.9) | 29 (7.3) | 7 (10.9) | 7 (12.7) |